  2 Diurnal Group plc _ Annual Report 2017 Strategy for success Diurnal aims to develop and commercialise products to address  unmet patient needs in chronic endocrine (hormonal) diseases,  typically where there is either no licensed medicine or where  current treatment does not sufficiently improve patients’ health. Diurnal is able to gain valuable  insights into the burden of living with these diseases through our  interaction with physicians and patient groups. The US remains a key market for Diurnal and the Group intends  to progress the Phase III development of both Infacort ®  and  Chronocort ®  in this region during the new financial year, whilst  assessing the optimal commercialisation strategy, in parallel. Meeting milestones, building our future Chairman’s statement It is with great pleasure that I report on the  significant progress Diurnal has made this  financial year towards becoming a world-leading,  endocrinology-focused specialty pharma  company. Richard’s extensive experience in corporate roles within the  biotechnology and pharmaceutical sector, with a particular focus  on financing, investor relations and business development, will be  invaluable as the Group executes its ambitious development plans. + Trusted consultants and contractors bringing expertise  to Diurnal’s development, manufacturing and  commercialisation activities. Building a flexible and responsive organisation Read more about Chronocort®   on page 20 20 Diurnal employees Consultants and contractors Development  12 Diurnal Group plc _ Annual Report 2017 Chief Executive’s review The financial year to 30 June 2017 has seen